Key Highlights
- Raised $130 million in Series D funding, led by Premji Invest.
- Funds to expand BillionToOne’s prenatal and oncology businesses.
- Quantitative Counting Templates™ technology offers single base-pair precision.
- UNITY Fetal Risk™ Screen provides unique prenatal insights without male partner blood sample.
- Northstar Select® and Northstar Response® enhance oncology diagnostics.
Source: PR Newswire
Notable Quote
- “At Premji Invest, we aim to partner with exceptional teams, solving difficult problems while building enduring businesses. We are thrilled to be a part of BillionToOne’s journey to create an industry-leading molecular diagnostics platform.” — Akshay Rai, Partner at Premji Invest
SoHC's Take
BillionToOne’s successful Series D funding round underscores the growing importance and potential of advanced molecular diagnostics in healthcare. With a significant infusion of $130 million, the company is well-positioned to scale its innovative prenatal and oncology diagnostic solutions. BillionToOne’s Quantitative Counting Templates™ technology, which allows for single base-pair precision in DNA counting, sets a new standard in the field, promising more accurate and accessible diagnostic options. The UNITY Fetal Risk™ Screen and Northstar oncology products exemplify the practical applications of this technology, addressing critical needs in prenatal care and cancer treatment. The involvement of prestigious investors like Premji Invest and Neuberger Berman further validates BillionToOne’s vision and potential for substantial impact in molecular diagnostics.
